Intended for investors: Today, we’re pleased to announce the completion of AstraZeneca’s acquisition of Amolyt Pharma, a global biopharmaceutical company specialising in rare endocrine and related diseases. This acquisition bolsters the Alexion, AstraZeneca Rare Disease pipeline and enables us to reach more patients living with #RareDiseases. Read more: https://learn.az/6042iOVpM
AstraZeneca is proud to welcome a French biotech of this quality! Beyond the hope that this represents for patients, this announcement also highlights the recognition of this French scientific excellence. The acquisition of Amolyt Pharma demonstrates once again AstraZeneca’s commitment to investing in the development of the medicines of the future, including biologics, as well as our significant footprint in France.
Congratulations! Thank you for helping those with that need it the most.
Very interesting! Congratulations, I hope yoy make a great difference for people with rear diseases 🎉
This is fantastic news!
Congratulations to AstraZeneca on the successful acquisition of Amolyt Pharma! This strategic acquisition is a significant step forward in expanding the Alexion, AstraZeneca Rare Disease pipeline. It highlights your commitment to addressing rare endocrine and related diseases, ultimately reaching more patients who need innovative treatments. We at PharmAllies applaud your dedication to advancing healthcare and improving patient outcomes.
Congratulations! Kudos to all your efforts in saving lives.
All advances in rare diseases are welcome for the benefits for the patients, familjes and their quality of life
Exciting news, AstraZeneca! Congratulations on completing the acquisition of Amolyt Pharma. This strategic move strengthens your position in rare endocrine and related diseases, expanding the potential to impact more patients globally. Looking forward to seeing the innovations that emerge from the bolstered Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease pipeline. #RareDiseases #Biopharma #HealthcareInnovation
Congratulations! I hope this provides patients the best solutions for rare diseases.
Congratulations on this acquisition! It is high time it drives the pipeline of #RareDiseases to improve patient outcomes.